{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:33:10Z","timestamp":1793424790657,"version":"4.5.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40272-022-00499-x","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T15:30:30Z","timestamp":1655134230000},"page":"293-305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":104,"title":["Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2760-0474","authenticated-orcid":false,"given":"Lawrence F.","family":"Eichenfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Stripling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selwyn","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andryann","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Schachner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"issue":"5","key":"499_CR1","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/pai.12095","volume":"24","author":"JI Silverberg","year":"2013","unstructured":"Silverberg JI, Simpson EL. Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization. Pediatr Allergy Immunol. 2013;24(5):476\u201386. https:\/\/doi.org\/10.1111\/pai.12095.","journal-title":"Pediatr Allergy Immunol"},{"issue":"suppl 1","key":"499_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000370220","volume":"66","author":"S Nutten","year":"2015","unstructured":"Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(suppl 1):8\u201316. https:\/\/doi.org\/10.1159\/000370220.","journal-title":"Ann Nutr Metab"},{"key":"499_CR3","doi-asserted-by":"publisher","unstructured":"Yang EJ, Sekhon S, Sanchez IM, Beck KM, Bhutani T. Recent developments in atopic dermatitis. Pediatrics. 2018;142(4). https:\/\/doi.org\/10.1542\/peds.2018-1102.","DOI":"10.1542\/peds.2018-1102"},{"issue":"1","key":"499_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0190-9622(94)70004-4","volume":"30","author":"J Kay","year":"1994","unstructured":"Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol. 1994;30(1):35\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"499_CR5","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","volume":"70","author":"LF Eichenfield","year":"2014","unstructured":"Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338\u201351. https:\/\/doi.org\/10.1016\/j.jaad.2013.10.010.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"499_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185066","volume":"12","author":"J Wang","year":"2017","unstructured":"Wang J, Ramette A, Jurca M, Goutaki M, Beardsmore CS, Kuehni CE. Association between breastfeeding and eczema during childhood and adolescence: a cohort study. PLoS\u00a0One. 2017;12(9):e0185066. https:\/\/doi.org\/10.1371\/journal.pone.0185066.","journal-title":"PLoS\u00a0One"},{"issue":"12","key":"499_CR7","doi-asserted-by":"publisher","first-page":"adv00160","DOI":"10.2340\/00015555-3510","volume":"100","author":"S Bylund","year":"2020","unstructured":"Bylund S, von Kobyletzki LB, Svalstedt M, Svensson A. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol. 2020;100(12):adv00160. https:\/\/doi.org\/10.2340\/00015555-3510.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"499_CR8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.det.2017.02.002","volume":"35","author":"JI Silverberg","year":"2017","unstructured":"Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35(3):283\u20139. https:\/\/doi.org\/10.1016\/j.det.2017.02.002.","journal-title":"Dermatol Clin"},{"issue":"1","key":"499_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","volume":"137","author":"AM Drucker","year":"2017","unstructured":"Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Investig Dermatol. 2017;137(1):26\u201330. https:\/\/doi.org\/10.1016\/j.jid.2016.07.012.","journal-title":"J Investig Dermatol"},{"issue":"4","key":"499_CR10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.anai.2018.12.017","volume":"122","author":"J Chung","year":"2019","unstructured":"Chung J, Simpson EL. The socioeconomics of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122(4):360\u20136. https:\/\/doi.org\/10.1016\/j.anai.2018.12.017.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"499_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3122\/jabfm.2019.02.180225","volume":"32","author":"J Al-Naqeeb","year":"2019","unstructured":"Al-Naqeeb J, Danner S, Fagnan LJ, et al. The burden of childhood atopic dermatitis in the primary care setting: a report from the Meta-LARC Consortium. J Am Board Fam Med. 2019;32(2):191\u2013200. https:\/\/doi.org\/10.3122\/jabfm.2019.02.180225.","journal-title":"J Am Board Fam Med"},{"issue":"3","key":"499_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.det.2017.02.003","volume":"35","author":"K Abuabara","year":"2017","unstructured":"Abuabara K, Margolis DJ, Langan SM. The long-term course of atopic dermatitis. Dermatol Clin. 2017;35(3):291\u20137. https:\/\/doi.org\/10.1016\/j.det.2017.02.003.","journal-title":"Dermatol Clin"},{"key":"499_CR13","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9899.1000202","author":"SK Bantz","year":"2014","unstructured":"Bantz SK, Zhu Z, Zheng T. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. J Clin Cell Immunol. 2014;5(2):202. https:\/\/doi.org\/10.4172\/2155-9899.1000202.","journal-title":"J Clin Cell Immunol"},{"issue":"5","key":"499_CR14","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/bjd.14697","volume":"175","author":"MA Strom","year":"2016","unstructured":"Strom MA, Fishbein AB, Paller AS, Silverberg JI. Association between atopic dermatitis and attention deficit hyperactivity disorder in US children and adults. Br J Dermatol. 2016;175(5):920\u20139. https:\/\/doi.org\/10.1111\/bjd.14697.","journal-title":"Br J Dermatol"},{"issue":"2","key":"499_CR15","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jaci.2012.10.041","volume":"131","author":"P Yaghmaie","year":"2013","unstructured":"Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131(2):428\u201333. https:\/\/doi.org\/10.1016\/j.jaci.2012.10.041.","journal-title":"J Allergy Clin Immunol"},{"key":"499_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-5945-12-11","volume":"12","author":"LB von Kobyletzki","year":"2012","unstructured":"von Kobyletzki LB, Bornehag CG, Hasselgren M, Larsson M, Lindstr\u00f6m CB, Svensson \u00c5. Eczema in early childhood is strongly associated with the development of asthma and rhinitis in a prospective cohort. BMC Dermatol. 2012;12:11. https:\/\/doi.org\/10.1186\/1471-5945-12-11.","journal-title":"BMC Dermatol"},{"issue":"4","key":"499_CR17","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.jaci.2015.10.049","volume":"137","author":"T Tsakok","year":"2016","unstructured":"Tsakok T, Marrs T, Mohsin M, et al. Does atopic dermatitis cause food allergy? A systematic review. J Allergy Clin Immunol. 2016;137(4):1071\u20138. https:\/\/doi.org\/10.1016\/j.jaci.2015.10.049.","journal-title":"J Allergy Clin Immunol"},{"issue":"6 Suppl","key":"499_CR18","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.1016\/j.jaci.2003.09.032","volume":"112","author":"N Novak","year":"2003","unstructured":"Novak N, Bieber T, Leung DY. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol. 2003;112(6 Suppl):S128\u201339. https:\/\/doi.org\/10.1016\/j.jaci.2003.09.032.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"499_CR19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.det.2017.02.006","volume":"35","author":"K Malik","year":"2017","unstructured":"Malik K, Heitmiller KD, Czarnowicki T. An update on the pathophysiology of atopic dermatitis. Dermatol Clin. 2017;35(3):317\u201326. https:\/\/doi.org\/10.1016\/j.det.2017.02.006.","journal-title":"Dermatol Clin"},{"key":"499_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/CCID.S130013","volume":"10","author":"U Wollina","year":"2017","unstructured":"Wollina U. Microbiome in atopic dermatitis. Clin Cosmet Investig Dermatol. 2017;10:51\u20136. https:\/\/doi.org\/10.2147\/CCID.S130013.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"499_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s41232-017-0044-7","volume":"37","author":"P Rerknimitr","year":"2017","unstructured":"Rerknimitr P, Otsuka A, Nakashima C, Kabashima K. The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. Inflamm Regen. 2017;37:14. https:\/\/doi.org\/10.1186\/s41232-017-0044-7.","journal-title":"Inflamm Regen"},{"key":"499_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13223-016-0158-5","volume":"12","author":"L Bin","year":"2016","unstructured":"Bin L, Leung DY. Genetic and epigenetic studies of atopic dermatitis. Allergy Asthma Clin Immunol. 2016;12:52. https:\/\/doi.org\/10.1186\/s13223-016-0158-5.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"499_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1655137","author":"MJ Cork","year":"2019","unstructured":"Cork MJ, Danby SG, Ogg GS. Atopic dermatitis epidemiology and unmet need in the United Kingdom. J Dermatol Treat. 2019;8:801\u20139. https:\/\/doi.org\/10.1080\/09546634.2019.1655137.","journal-title":"J Dermatol Treat"},{"issue":"12","key":"499_CR24","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/1346-8138.13072","volume":"42","author":"CE Powers","year":"2015","unstructured":"Powers CE, McShane DB, Gilligan PH, Burkhart CN, Morrell DS. Microbiome and pediatric atopic dermatitis. J Dermatol. 2015;42(12):1137\u201342. https:\/\/doi.org\/10.1111\/1346-8138.13072.","journal-title":"J Dermatol"},{"issue":"1","key":"499_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5114\/ada.2019.82821","volume":"36","author":"L Blicharz","year":"2019","unstructured":"Blicharz L, Rudnicka L, Samochocki Z. Staphylococcus aureus: an underestimated factor in the pathogenesis of atopic dermatitis? Postep Dermatol Alergol. 2019;36(1):11\u20137. https:\/\/doi.org\/10.5114\/ada.2019.82821.","journal-title":"Postep Dermatol Alergol"},{"issue":"4","key":"499_CR26","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","volume":"147","author":"Y Renert-Yuval","year":"2021","unstructured":"Renert-Yuval Y, Thyssen JP, Bissonnette R, et al. Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council. J Allergy Clin Immunol. 2021;147(4):1174-90.e1. https:\/\/doi.org\/10.1016\/j.jaci.2021.01.013.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"499_CR27","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3390\/jcm4050858","volume":"4","author":"Y Mansouri","year":"2015","unstructured":"Mansouri Y, Guttman-Yassky E. Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med. 2015;4(5):858\u201373. https:\/\/doi.org\/10.3390\/jcm4050858.","journal-title":"J Clin Med"},{"issue":"6","key":"499_CR28","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.jaci.2016.07.013","volume":"138","author":"H Esaki","year":"2016","unstructured":"Esaki H, Brunner PM, Renert-Yuval Y, et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. J Allergy Clin Immunol. 2016;138(6):1639\u201351. https:\/\/doi.org\/10.1016\/j.jaci.2016.07.013.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"499_CR29","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1016\/j.jaci.2018.02.040","volume":"141","author":"PM Brunner","year":"2018","unstructured":"Brunner PM, Israel A, Zhang N, et al. Early-onset pediatric atopic dermatitis is characterized by TH2\/TH17\/TH22-centered inflammation and lipid alterations. J Allergy Clin Immunol. 2018;141(6):2094\u2013106. https:\/\/doi.org\/10.1016\/j.jaci.2018.02.040.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"499_CR30","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jaad.2019.04.036","volume":"81","author":"PM Brunner","year":"2019","unstructured":"Brunner PM, He H, Pavel AB, et al. The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease. J Am Acad Dermatol. 2019;81(2):510\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2019.04.036.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"499_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/exd.13808","volume":"28","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Hanifin JM, Boguniewicz M, et al. The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition. Exp Dermatol. 2019;28(1):3\u201310. https:\/\/doi.org\/10.1111\/exd.13808.","journal-title":"Exp Dermatol"},{"issue":"8","key":"499_CR32","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1001\/archdermatol.2012.812","volume":"148","author":"A Samrao","year":"2012","unstructured":"Samrao A, Berry TM, Goreshi R, Simpson EL. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol. 2012;148(8):890\u20137. https:\/\/doi.org\/10.1001\/archdermatol.2012.812.","journal-title":"Arch Dermatol"},{"issue":"3","key":"499_CR33","doi-asserted-by":"publisher","DOI":"10.4161\/jkst.24137","volume":"2","author":"L Bao","year":"2013","unstructured":"Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013;2(3):e24137. https:\/\/doi.org\/10.4161\/jkst.24137.","journal-title":"JAKSTAT"},{"key":"499_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay1005","author":"MR Mack","year":"2020","unstructured":"Mack MR, Brestoff JR, Berrien-Elliott MM, et al. Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis. Sci Transl Med. 2020;12(532):eaay1005. https:\/\/doi.org\/10.1126\/scitranslmed.aay1005.","journal-title":"Sci Transl Med"},{"issue":"1","key":"499_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.anai.2020.08.002","volume":"126","author":"V Wang","year":"2021","unstructured":"Wang V, Boguniewicz J, Boguniewicz M, Ong PY. The infectious complications of atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):3\u201312. https:\/\/doi.org\/10.1016\/j.anai.2020.08.002.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"12","key":"499_CR36","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1080\/03007995.2018.1498329","volume":"34","author":"AA Hebert","year":"2018","unstructured":"Hebert AA, Stingl G, Ho LK, et al. Patient impact and economic burden of mild-to-moderate atopic dermatitis. Curr Med Res Opin. 2018;34(12):2177\u201385. https:\/\/doi.org\/10.1080\/03007995.2018.1498329.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"499_CR37","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1525-1470.2005.22303.x","volume":"22","author":"CL Carroll","year":"2005","unstructured":"Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB Jr, Manuel JC. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005;22(3):192\u20139. https:\/\/doi.org\/10.1111\/j.1525-1470.2005.22303.x.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"499_CR38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/archpedi.153.3.249","volume":"153","author":"H Reuveni","year":"1999","unstructured":"Reuveni H, Chapnick G, Tal A, Tarasiuk A. Sleep fragmentation in children with atopic dermatitis. Arch Pediatr Adolesc Med. 1999;153(3):249\u201353. https:\/\/doi.org\/10.1001\/archpedi.153.3.249.","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"1","key":"499_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2500\/aap.2017.38.4005","volume":"38","author":"AM Drucker","year":"2017","unstructured":"Drucker AM. Atopic dermatitis: burden of illness, quality of life, and associated complications. Allergy Asthma Proc. 2017;38(1):3\u20138. https:\/\/doi.org\/10.2500\/aap.2017.38.4005.","journal-title":"Allergy Asthma Proc"},{"issue":"5","key":"499_CR40","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2019.0025","volume":"173","author":"FD Ramirez","year":"2019","unstructured":"Ramirez FD, Chen S, Langan SM, et al. Association of atopic dermatitis with sleep quality in children. JAMA Pediatr. 2019;173(5): e190025. https:\/\/doi.org\/10.1001\/jamapediatrics.2019.0025.","journal-title":"JAMA Pediatr"},{"issue":"3","key":"499_CR41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.12788\/cutis.0077","volume":"106","author":"A Tracy","year":"2020","unstructured":"Tracy A, Bhatti S, Eichenfield LF. Update on pediatric atopic dermatitis. Cutis. 2020;106(3):143\u20136. https:\/\/doi.org\/10.12788\/cutis.0077.","journal-title":"Cutis"},{"issue":"5","key":"499_CR42","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1001\/jamadermatol.2018.5641","volume":"155","author":"FD Ramirez","year":"2019","unstructured":"Ramirez FD, Chen S, Langan SM, et al. Assessment of sleep disturbances and exhaustion in mothers of children with atopic dermatitis. JAMA Dermatol. 2019;155(5):556\u201363.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"499_CR43","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1177\/1203475418761859","volume":"22","author":"AC Bridgman","year":"2018","unstructured":"Bridgman AC, Eshtiaghi P, Cresswell-Melville A, Ramien M, Drucker AM. The burden of moderate to severe atopic dermatitis in Canadian children: a cross-sectional survey. J Cutan Med Surg. 2018;22(4):443\u20134. https:\/\/doi.org\/10.1177\/1203475418761859.","journal-title":"J Cutan Med Surg"},{"issue":"8","key":"499_CR44","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1001\/jamadermatol.2019.0597","volume":"155","author":"J Wan","year":"2019","unstructured":"Wan J, Margolis DJ, Mitra N, Hoffstad OJ, Takeshita J. Racial and ethnic differences in atopic dermatitis-related school absences among US children. JAMA Dermatol. 2019;155(8):973\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2019.0597.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"499_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171394","volume":"12","author":"SY Kim","year":"2017","unstructured":"Kim SY, Kim MS, Park B, Kim JH, Choi HG. Allergic rhinitis, atopic dermatitis, and asthma are associated with differences in school performance among Korean adolescents. PLoS\u00a0One. 2017;12(2):e0171394. https:\/\/doi.org\/10.1371\/journal.pone.0171394.","journal-title":"PLoS\u00a0One"},{"issue":"3","key":"499_CR46","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1471-6712.2007.00547.x","volume":"22","author":"P Magin","year":"2008","unstructured":"Magin P, Adams J, Heading G, Pond D, Smith W. Experiences of appearance-related teasing and bullying in skin diseases and their psychological sequelae: results of a qualitative study. Scand J Caring Sci. 2008;22(3):430\u20136. https:\/\/doi.org\/10.1111\/j.1471-6712.2007.00547.x.","journal-title":"Scand J Caring Sci"},{"issue":"1","key":"499_CR47","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jaci.2006.02.031","volume":"118","author":"T Zuberbier","year":"2006","unstructured":"Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):226\u201332. https:\/\/doi.org\/10.1016\/j.jaci.2006.02.031.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"499_CR48","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1542\/peds.2004-0374","volume":"114","author":"SL Chamlin","year":"2004","unstructured":"Chamlin SL, Frieden IJ, Williams ML, Chren MM. Effects of atopic dermatitis on young American children and their families. Pediatrics. 2004;114(3):607\u201311. https:\/\/doi.org\/10.1542\/peds.2004-0374.","journal-title":"Pediatrics"},{"key":"499_CR49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2147\/ccid.S91263","volume":"9","author":"PV Chernyshov","year":"2016","unstructured":"Chernyshov PV. Stigmatization and self-perception in children with atopic dermatitis. Clin Cosmet Investig Dermatol. 2016;9:159\u201366. https:\/\/doi.org\/10.2147\/ccid.S91263.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"499_CR50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12888-016-1160-7","volume":"17","author":"S Lee","year":"2017","unstructured":"Lee S, Shin A. Association of atopic dermatitis with depressive symptoms and suicidal behaviors among adolescents in Korea: the 2013 Korean Youth Risk Behavior Survey. BMC Psychiatry. 2017;17(1):3. https:\/\/doi.org\/10.1186\/s12888-016-1160-7.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"499_CR51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.anai.2020.03.023","volume":"125","author":"Y Kyung","year":"2020","unstructured":"Kyung Y, Choi MH, Jeon YJ, et al. Association of atopic dermatitis with suicide risk among 788,411 adolescents: a Korean cross-sectional study. Ann Allergy Asthma Immunol. 2020;125(1):55\u201364. https:\/\/doi.org\/10.1016\/j.anai.2020.03.023.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"499_CR52","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaad.2018.03.017","volume":"79","author":"ATM Ronnstad","year":"2018","unstructured":"Ronnstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis. J Am Acad Dermatol. 2018;79(3):448-56.e30. https:\/\/doi.org\/10.1016\/j.jaad.2018.03.017.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"499_CR53","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1590\/1984-0462\/;2017;35;1;00006","volume":"35","author":"ALB Campos","year":"2017","unstructured":"Campos ALB, Ara\u00fajo FM, Santos M, Santos A, Pires CAA. Impact of atopic dermatitis on the quality of life of pediatric patients and their guardians. Rev Paul Pediatr. 2017;35(1):5\u201310. https:\/\/doi.org\/10.1590\/1984-0462\/;2017;35;1;00006.","journal-title":"Rev Paul Pediatr"},{"issue":"1","key":"499_CR54","doi-asserted-by":"publisher","first-page":"15990","DOI":"10.1038\/s41598-019-51129-5","volume":"9","author":"X Xu","year":"2019","unstructured":"Xu X, van Galen LS, Koh MJA, et al. Factors influencing quality of life in children with atopic dermatitis and their caregivers: a cross-sectional study. Sci Rep. 2019;9(1):15990. https:\/\/doi.org\/10.1038\/s41598-019-51129-5.","journal-title":"Sci Rep"},{"issue":"3","key":"499_CR55","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/der.0000000000000582","volume":"31","author":"K Capozza","year":"2020","unstructured":"Capozza K, Gadd H, Kelley K, Russell S, Shi V, Schwartz A. Insights from caregivers on the impact of pediatric atopic dermatitis on families: \u201cI\u2019m tired, overwhelmed, and feel like i\u2019m failing as a mother.\u2019. Dermatitis. 2020;31(3):223\u20137. https:\/\/doi.org\/10.1097\/der.0000000000000582.","journal-title":"Dermatitis"},{"key":"499_CR56","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pedn.2016.11.007","volume":"33","author":"LL Gan","year":"2017","unstructured":"Gan LL, Lum A, Wakefield CE, Nandakumar B, Fardell JE. School experiences of siblings of children with chronic illness: a systematic literature review. J Pediatr Nurs. 2017;33:23\u201332. https:\/\/doi.org\/10.1016\/j.pedn.2016.11.007.","journal-title":"J Pediatr Nurs"},{"issue":"2","key":"499_CR57","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/jpepsy\/jsr081","volume":"37","author":"IP Vermaes","year":"2012","unstructured":"Vermaes IP, van Susante AM, van Bakel HJ. Psychological functioning of siblings in families of children with chronic health conditions: a meta-analysis. J Pediatr Psychol. 2012;37(2):166\u201384. https:\/\/doi.org\/10.1093\/jpepsy\/jsr081.","journal-title":"J Pediatr Psychol"},{"issue":"92","key":"499_CR58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2340\/00015555924447","volume":"60","author":"JM Hanifin","year":"1980","unstructured":"Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol. 1980;60(92):44\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"499_CR59","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1365-2133.1994.tb08531.x","volume":"131","author":"HC Williams","year":"1994","unstructured":"Williams HC, Burney PG, Strachan D, Hay RJ. The U.K. Working Party\u2019s Diagnostic Criteria for Atopic Dermatitis. II. Observer variation of clinical diagnosis and signs of atopic dermatitis. Br J Dermatol. 1994;131(3):397\u2013405.","journal-title":"Br J Dermatol"},{"issue":"4S","key":"499_CR60","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.jaci.2017.01.009","volume":"139","author":"LF Eichenfield","year":"2017","unstructured":"Eichenfield LF, Ahluwalia J, Waldman A, Borok J, Udkoff J, Boguniewicz M. Current guidelines for the evaluation and management of atopic dermatitis: a comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines. J Allergy Clin Immunol. 2017;139(4S):S49\u201357. https:\/\/doi.org\/10.1016\/j.jaci.2017.01.009.","journal-title":"J Allergy Clin Immunol"},{"issue":"5_suppl","key":"499_CR61","doi-asserted-by":"publisher","first-page":"3s","DOI":"10.1177\/1203475419882049","volume":"23","author":"I Lara-Corrales","year":"2019","unstructured":"Lara-Corrales I, Bergman JN, Landells I, Ramien ML, Lansang P. Approach to the assessment and management of pediatric patients with atopic dermatitis: a consensus document. Section I: overview of pediatric atopic dermatitis. J Cutan Med Surg. 2019;23(5_suppl):3s\u201311s. https:\/\/doi.org\/10.1177\/1203475419882049.","journal-title":"J Cutan Med Surg"},{"issue":"10","key":"499_CR62","first-page":"590","volume":"101","author":"W Frazier","year":"2020","unstructured":"Frazier W, Bhardwaj N. Atopic dermatitis: diagnosis and treatment. Am Fam Physician. 2020;101(10):590\u20138.","journal-title":"Am Fam Physician"},{"issue":"2","key":"499_CR63","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jaad.2015.09.062","volume":"74","author":"M Futamura","year":"2016","unstructured":"Futamura M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol. 2016;74(2):288\u201394. https:\/\/doi.org\/10.1016\/j.jaad.2015.09.062.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"499_CR64","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/bjd.13662","volume":"172","author":"YA Leshem","year":"2015","unstructured":"Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353\u20137. https:\/\/doi.org\/10.1111\/bjd.13662.","journal-title":"Br J Dermatol"},{"issue":"1","key":"499_CR65","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000245677","volume":"195","author":"B Kunz","year":"1997","unstructured":"Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10\u20139. https:\/\/doi.org\/10.1159\/000245677.","journal-title":"Dermatology"},{"issue":"6","key":"499_CR66","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/bjd.12590","volume":"169","author":"CR Charman","year":"2013","unstructured":"Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013;169(6):1326\u201332. https:\/\/doi.org\/10.1111\/bjd.12590.","journal-title":"Br J Dermatol"},{"issue":"5","key":"499_CR67","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jaad.2019.12.055","volume":"82","author":"YA Leshem","year":"2020","unstructured":"Leshem YA, Chalmers JR, Apfelbacher C, et al. Measuring atopic eczema symptoms in clinical practice: the first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative. J Am Acad Dermatol. 2020;82(5):1181\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2019.12.055.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"499_CR68","first-page":"83","volume":"12","author":"SR Feldman","year":"2019","unstructured":"Feldman SR, Cox LS, Strowd LC, et al. The challenge of managing atopic dermatitis in the United States. Am Health Drug Benefits. 2019;12(2):83\u201393.","journal-title":"Am Health Drug Benefits"},{"issue":"5","key":"499_CR69","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/jdv.14891","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657\u201382. https:\/\/doi.org\/10.1111\/jdv.14891.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"499_CR70","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.14888","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850\u201378. https:\/\/doi.org\/10.1111\/jdv.14888.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"499_CR71","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","volume":"120","author":"M Boguniewicz","year":"2018","unstructured":"Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10-22.e2. https:\/\/doi.org\/10.1016\/j.anai.2017.10.039.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"499_CR72","unstructured":"National Institute for Heath and Care Excellence. Atopic eczema in under 12s. National Institute for Heath and Care Excellence, London, UK. 2013. https:\/\/www.nice.org.uk\/guidance\/QS44. Accessed 27 Aug 2020."},{"issue":"6","key":"499_CR73","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/pde.13862","volume":"36","author":"KE Oberlin","year":"2019","unstructured":"Oberlin KE, Nanda S. Atopic dermatitis made easy: the Schachner ladder. Pediatr Dermatol. 2019;36(6):1017\u20138.","journal-title":"Pediatr Dermatol"},{"issue":"5_suppl","key":"499_CR74","doi-asserted-by":"publisher","first-page":"32s","DOI":"10.1177\/1203475419882654","volume":"23","author":"P Lansang","year":"2019","unstructured":"Lansang P, Lara-Corrales I, Bergman JN, et al. Approach to the assessment and management of pediatric patients with atopic dermatitis: a consensus document. Section IV: consensus statements on the assessment and management of pediatric atopic dermatitis. J Cutan Med Surg. 2019;23(5_suppl):32s-s39. https:\/\/doi.org\/10.1177\/1203475419882654.","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"499_CR75","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40521-017-0140-6","volume":"4","author":"A Huang","year":"2017","unstructured":"Huang A, Cho C, Leung DYM, Brar K. Atopic dermatitis: early treatment in children. Curr Treat Options Allergy. 2017;4(3):355\u201369. https:\/\/doi.org\/10.1007\/s40521-017-0140-6.","journal-title":"Curr Treat Options Allergy"},{"key":"499_CR76","unstructured":"Derma-Smoothe. Prescribing information. Stanford: Hill Dermaceuticals, Inc.; 2007."},{"issue":"4","key":"499_CR77","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40272-019-00342-w","volume":"21","author":"HL Nguyen","year":"2019","unstructured":"Nguyen HL, Anderson KR, Tollefson MM. New and emerging therapies for pediatric atopic dermatitis. Paediatr Drugs. 2019;21(4):239\u201360. https:\/\/doi.org\/10.1007\/s40272-019-00342-w.","journal-title":"Paediatr Drugs"},{"issue":"2","key":"499_CR78","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40257-020-00510-6","volume":"21","author":"J Schlessinger","year":"2020","unstructured":"Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to <\u00a024\u00a0months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol. 2020;21(2):275\u201384. https:\/\/doi.org\/10.1007\/s40257-020-00510-6.","journal-title":"Am J Clin Dermatol"},{"key":"499_CR79","unstructured":"Elidel. Prescribing information. Valeant Pharmaceuticals North America; 2014."},{"key":"499_CR80","unstructured":"Protopic. Prescribing information. Astellas Pharma Tech Co., Ltd.; 2016."},{"issue":"2","key":"499_CR81","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","volume":"71","author":"R Sidbury","year":"2014","unstructured":"Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327\u201349. https:\/\/doi.org\/10.1016\/j.jaad.2014.03.030.","journal-title":"J Am Acad Dermatol"},{"key":"499_CR82","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0796","author":"AM Drucker","year":"2020","unstructured":"Drucker AM, Ellis AG, Bohdanowicz M, et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol. 2020. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0796.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"499_CR83","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","volume":"83","author":"AS Paller","year":"2020","unstructured":"Paller AS, Siegfried EC, Tha\u00e7i D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11\u00a0years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282\u201393. https:\/\/doi.org\/10.1016\/j.jaad.2020.06.054.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"499_CR84","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1370\/afm.2038","volume":"15","author":"NA Francis","year":"2017","unstructured":"Francis NA, Ridd MJ, Thomas-Jones E, et al. Oral and topical antibiotics for clinically infected eczema in children: a pragmatic randomized controlled trial in ambulatory care. Ann Fam Med. 2017;15(2):124\u201330. https:\/\/doi.org\/10.1370\/afm.2038.","journal-title":"Ann Fam Med"},{"issue":"4","key":"499_CR85","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.jaip.2021.02.017","volume":"9","author":"JB Mancuso","year":"2021","unstructured":"Mancuso JB, Lee SS, Paller AS, Ohya Y, Eichenfield LF. Management of severe atopic dermatitis in pediatric patients. J Allergy Clin Immunol Pract. 2021;9(4):1462\u201371. https:\/\/doi.org\/10.1016\/j.jaip.2021.02.017.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"499_CR86","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.jaad.2014.08.038","volume":"71","author":"R Sidbury","year":"2014","unstructured":"Sidbury R, Tom WL, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014;71(6):1218\u201333. https:\/\/doi.org\/10.1016\/j.jaad.2014.08.038.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"499_CR87","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","volume":"155","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2019.2855.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"499_CR88","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","volume":"145","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Thaci D, Pangan AL, et al. Upadacitinib in adults with moderate-to-severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2019;145(3):877\u201384. https:\/\/doi.org\/10.1016\/j.jaci.2019.11.025.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"499_CR89","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","volume":"143","author":"A Wollenberg","year":"2019","unstructured":"Wollenberg A, Howell MD, Guttman-Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019;143(1):135\u201341. https:\/\/doi.org\/10.1016\/j.jaci.2018.05.029.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"499_CR90","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","volume":"78","author":"EL Simpson","year":"2018","unstructured":"Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863-71. e11. https:\/\/doi.org\/10.1016\/j.jaad.2018.01.017.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"499_CR91","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863\u201373. https:\/\/doi.org\/10.1001\/jamadermatol.2020.1406.","journal-title":"JAMA Dermatol"},{"issue":"10246","key":"499_CR92","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/s0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255\u201366. https:\/\/doi.org\/10.1016\/s0140-6736(20)30732-7.","journal-title":"Lancet"},{"key":"499_CR93","unstructured":"European Medicines Agency. EMEA-001741-PIP04-17-M01. European Medicines Agency, Amsterdam, Netherlands. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/paediatric-investigation-plans\/emea-001741-pip04-17-m01. Accessed 06 Dec 2021."},{"key":"499_CR94","unstructured":"Pharmaceuticals and Medical Devices Agency. List of Approved Products (New Drugs): FY 2021 (April 2021\u2013November 2021). Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. https:\/\/www.pmda.go.jp\/files\/000243812.pdf. Accessed 06 Dec 2021."},{"issue":"2","key":"499_CR95","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242\u201355. https:\/\/doi.org\/10.1111\/bjd.18898.","journal-title":"Br J Dermatol"},{"key":"499_CR96","unstructured":"Olumiant. Summary of product characteristics. Utrecht: Eli Lilly Nederland B.V.; 2020."},{"issue":"2","key":"499_CR97","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1651-2227.2008.01033.x","volume":"98","author":"TS Bergmo","year":"2009","unstructured":"Bergmo TS, Wangberg SC, Schopf TR, Solvoll T. Web-based consultations for parents of children with atopic dermatitis: results of a randomized controlled trial. Acta Paediatr. 2009;98(2):316\u201320. https:\/\/doi.org\/10.1111\/j.1651-2227.2008.01033.x.","journal-title":"Acta Paediatr"},{"key":"499_CR98","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1756-0500-3-71","volume":"3","author":"TR Schopf","year":"2010","unstructured":"Schopf TR, Bolle R, Solvoll T. The workload of web-based consultations with atopic eczema patients at home. BMC Res Notes. 2010;3:71. https:\/\/doi.org\/10.1186\/1756-0500-3-71.","journal-title":"BMC Res Notes"},{"issue":"8","key":"499_CR99","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/j.1398-9995.2011.02577.x","volume":"66","author":"JF Stalder","year":"2011","unstructured":"Stalder JF, Barbarot S, Wollenberg A, et al. Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy. 2011;66(8):1114\u201321. https:\/\/doi.org\/10.1111\/j.1398-9995.2011.02577.x.","journal-title":"Allergy"},{"issue":"12","key":"499_CR100","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","volume":"140","author":"CR Charman","year":"2004","unstructured":"Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective. Arch Dermatol. 2004;140(12):1513\u20139. https:\/\/doi.org\/10.1001\/archderm.140.12.1513.","journal-title":"Arch Dermatol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00499-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-022-00499-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00499-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T21:25:17Z","timestamp":1700688317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-022-00499-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["499"],"URL":"https:\/\/doi.org\/10.1007\/s40272-022-00499-x","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]},"assertion":[{"value":"8 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Pfizer Inc.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"LFE has served as a scientific adviser, consultant, and\/or clinical study investigator for Pfizer Inc., AbbVie, Almirall, Amgen, Asana Biosciences, Cutanea, Dermavant, Dermira, Dr. Reddy\u2019s Laboratory, DS Biopharma, Eli Lilly, Fort\u00e9 Pharma, Galderma, Glenmark, Incyte, LEO Pharma, Matrisys Bioscience, Novan, Novartis, Ortho Dermatologics\/Valeant, Sanofi Regeneron, Sanofi Genzyme, TopMD, UCB, and Verrica. SS has served as a scientific adviser, consultant, and\/or clinical study investigator for Pfizer Inc. SF, AC, and AOB are employees of and own stock in Pfizer, Inc. LAS has served as a scientific advisor, consultant, lecturer and\/or on advisory boards for Pfizer, Mustela, CeraVe, Sanofi-Regeneron, Hoth, Alphyn, TopMD, and Verrica.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors made substantial contributions to the conception or design of the work, revised it critically for important intellectual content, approved the version to be published, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}